Phosplatin Therapeutics Announces Publication in OncoImmunology

Immunogenic Cell Death (ICD) Effects of PT-112 Confirmed via in vitro and in vivo Experiments

Anti-Cancer Immunity Observed Across Vaccination, Abscopal and Tumor Allograft Models

NEW YORK, Feb. 18, 2020 /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology drug development, announced its publication in OncoImmunology of in vitro and in vivo data demonstrating that PT-112 is a bona fide immunogenic cell death (ICD) inducer, and as a result can initiate anticancer immunity, as a monotherapy and in combination with immune checkpoint inhibition.

PT-112 causes the release of so-called damage associated molecular patterns (DAMPs), a signature of ICD, by dying cancer cells. In addition, PT-112 synergizes with immune checkpoint blockers (ICBs) in the context of superior immune infiltration. These findings are in line with preliminary clinical evidence on the use of PT-112 in patients with solid tumors, either as a monotherapy or in combination with anti-PD-L1 immune checkpoint blockade.

"As a stand-alone agent, PT-112 has been validated as a potent ICD inducer," said Lorenzo Galluzzi, PhD, Assistant Professor of Cell Biology in Radiation Oncology at Weill Cornell Medical College, and senior author of the article. "Our model systems are designed to isolate the immune effects of a given agent, and PT-112 showed positive results across all model systems deployed thus far." "We have been delighted with our collaboration with Dr. Galluzzi and his laboratory team at Weill Cornell," said Matthew R. Price, Executive Vice President & COO at Phosplatin Therapeutics. "This publication underscores PT-112's role within the emerging field of immunotherapy, and its potential as a best-in-class ICD inducer."

Along with ICD induction, PT-112 possesses a unique combination of factors, including safety in heavily pre-treated patients, single-agent activity in patients with lung cancers, prostate cancer and thymoma. In addition, the pyrophosphate component of the drug is believed to be responsible for bio-distribution that includes high drug concentrations in mineralized bone (osteotropism). PT-112's features make it a promising candidate for the treatment of cancers that frequently metastasize to bone and/or are not likely to respond to checkpoint inhibitors.

Please refer to the OncoImmunology paper, "PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models," (Issue 9, Vol. 1) for the full description of the design and results of this work. The publication is available online here.

Further information on clinical trials with PT-112 that are currently open can be found at the clinicaltrials.gov registry under NCT 02266745NCT 03409458, and NCT03288480.

About PT-112

PT-112 is a novel anti-cancer agent, the first cytotoxic small molecule conjugate of pyrophosphate developed in oncology therapeutics. PT-112 promotes immunogenic cell death (ICD), or the release of damage associated molecular patterns (DAMPs) that lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents a potential best-in-class small molecule inducer of this immunological form of cancer cell death. The first-in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses and tumor control among heavily pre-treated patients, and was presented at the ESMO 2018 Annual Congress, winning "Best Poster" among the Developmental Therapeutics category. The novelty of its pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in bone, or frequently lead to metastatic bone involvement, such as metastatic castrate-resistant prostate cancer mCRPC. The first human clinical results in mCRPC were presented at the 2020 Genitourinary Cancers Symposium on February 13, 2020.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a private, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The lead candidate, PT-112, is a novel chemical entity under clinical development that combines apoptotic and immunological properties in combating cancer. Clinical data generated to date across three studies have demonstrated single agent anti-cancer activity and an attractive tolerability profile. The company's research and development work to date has spanned fifteen countries and been funded by private investors and family investment offices in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. 

See: www.phosplatin.com.

Contact: info@phosplatin.com 

SOURCE Phosplatin Therapeutics

Related Links

http://phosplatin.com

Previous
Previous

Phosplatin Therapeutics Receives Notice of US Patent Issuance for PT-112 as Therapeutic Agent for Treatment of Bone or Blood Cancers

Next
Next

Phosplatin Therapeutics presents positive data from two phase I studies in metastatic castrate-resistant prostate cancer patients at the Genitourinary Cancers Symposium